Preclinical evaluation of the novel [¹⁸F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington's disease.

ABSTRACT:

Purpose

Positron emission tomography (PET) imaging of mutant huntingtin (mHTT) aggregates is a potential tool to monitor disease progression as well as the efficacy of candidate therapeutic interventions for Huntington's disease (HD). To date, the focus has been mainly on the investigation of ¹¹C radioligands; however, favourable ¹⁸F radiotracers will facilitate future clinical translation. This work aimed at characterising the novel [¹⁸F]CHDI-650 PET radiotracer using a combination of in vivo and in vitro approaches in a mouse model of HD.

Methods

After characterising [¹⁸F]CHDI-650 using in vitro autoradiography, we assessed in vivo plasma and brain radiotracer stability as well as kinetics through dynamic PET imaging in the heter

SUBMITTER: Zajicek F 

PROVIDER: S-EPMC11599348 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature